Nasdaq · Pharmaceutical Preparations
Quote as of Oct 9, 2:30 PM ET · delayed
Fairly Valued. Our fair value estimate is USD 246.74 against a price of USD 230.77, +7% implied upside. Reasoning and scenarios are in Alnylam stock: TTR growth is strong, but the launch reset matters.
Alnylam stock is down 2.9% at $246.74, but the reason for today’s attention is unconfirmed. The latest documented catalyst is a lower TTR sales outlook despite rapid quarterly growth.
StockLarge CapHealthcareNo earnings notes for this company yet.
Revenue (USD, billions)
Margins (%)
Free cash flow (USD, billions)
Estimated ROIC (%)
Net debt (USD, billions)
Monetary values are in USD; revenue, FCF and net debt are in billions; EPS is per share. Missing values appear as gaps and “Not available.” Source: SEC EDGAR XBRL filings, latest restated values; quarterly cash flow derived from year-to-date figures; Q4 = fiscal year minus nine months. ROIC is NOPAT (21% tax) over debt plus equity.
| Period | Revenue | Gross % | Op % | FCF | EPS | ROIC % | Net debt |
|---|---|---|---|---|---|---|---|
| FY2016 | 0.05 | Not available | -900.3 | -0.37 | Not available | Not available | Not available |
| FY2017 | 0.09 | Not available | -556.2 | -0.49 | Not available | Not available | Not available |
| FY2018 | 0.07 | Not available | -1087.6 | -0.69 | Not available | Not available | Not available |
| FY2019 | 0.22 | Not available | -427.5 | -0.42 | -8.11 | Not available | Not available |
| FY2020 | 0.49 | Not available | -168.1 | -0.69 | -7.46 | -54.2 | -0.31 |
| FY2021 | 0.84 | Not available | -83.9 | -0.72 | -7.20 | -44.3 | -0.14 |
| FY2022 | 1.04 | Not available | -75.7 | -0.61 | -9.30 | Not available | Not available |
| FY2023 | 1.83 | Not available | -15.4 | 0.04 | -3.52 | Not available | Not available |
| FY2024 | 2.25 | Not available | -7.87 | -0.04 | -2.18 | Not available | Not available |
| FY2025 | 3.71 | Not available | 13.5 | 0.47 | 2.33 | Not available | Not available |
Current price
USD 230.77
Fair value estimate
USD 246.74
Implied upside
+6.9%
Bear
25%USD 210
Direct equity valuation using assumed equity value divided by diluted shares.
This case assumes normalized second-line demand grows too slowly to support the revised outlook over time and that launch costs and product royalties continue to limit operating leverage.
Base
50%USD 247
Direct equity valuation using assumed equity value divided by diluted shares.
This case assumes the revised commercial outlook is achievable, TTR demand continues to expand at a more normalized pace, and pipeline potential offsets rather than immediately replaces the franchise’s growth contribution.
Bull
25%USD 285
Direct equity valuation using assumed equity value divided by diluted shares.
This case assumes sustained AMVUTTRA demand, wider international contribution, and pipeline advancement support stronger long-run revenue and earnings capacity than the current price implies.
No news items logged for this company yet.